These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 24911993)

  • 21. Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China: a cross-sectional study.
    Chen Y; Wei L; Song Y; Zhang R; Kuai L; Li B; Wang R
    Ann Med; 2023 Dec; 55(1):2231847. PubMed ID: 37417705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PASI90 response: the new standard in therapeutic efficacy for psoriasis.
    Puig L
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):645-8. PubMed ID: 25370811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of CoQ10 Administration to Psoriatic Iraqi Patients on Biological Therapy Upon Severity Index (PASI) and Quality of Life Index (DLQI) Before and After Therapy.
    Al-Oudah GA; Sahib AS; Al-Hattab MK; Al-Ameedee AA
    J Popul Ther Clin Pharmacol; 2022; 29(2):e52-e60. PubMed ID: 35848197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
    Viswanathan HN; Mutebi A; Milmont CE; Gordon K; Wilson H; Zhang H; Klekotka PA; Revicki DA; Augustin M; Kricorian G; Nirula A; Strober B
    Value Health; 2017 Sep; 20(8):1174-1179. PubMed ID: 28964451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study.
    Loft ND; Egeberg A; Rasmussen MK; Bryld LE; Gniadecki R; Dam TN; Iversen L; Skov L
    Acta Derm Venereol; 2019 Dec; 99(13):1224-1230. PubMed ID: 31580465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life.
    Walker F; Adamczyk A; Kellerer C; Belge K; Brück J; Berner T; Merten K; Núnez Gómez N; Neureither M; Röcken M; Ghoreschi K;
    Br J Dermatol; 2014 Nov; 171(5):1197-205. PubMed ID: 24813676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
    Petridis A; Panagakis P; Moustou E; Vergou T; Kallidis P; Mandekou-Lefaki I; Chaidemenos G; Sotiriadis D; Alexopoulou G; Haratsis Y; Antoniou C
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study.
    Daudén E; Pujol RM; Sánchez-Carazo JL; Toribio J; Vanaclocha F; Puig L; Yébenes M; Sabater E; Casado MA; Caloto MT; Aragón B;
    Actas Dermosifiliogr; 2013 Nov; 104(9):807-14. PubMed ID: 23827342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measuring quality of life in patients with psoriasis using the Arabic version for Morocco of the Dermatology Life Quality Index.
    Khoudri I; Lamchahab FZ; Ismaili N; Senouci K; Hassam B; Abouqal R
    Int J Dermatol; 2013 Jul; 52(7):795-802. PubMed ID: 23488573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A higher score on the dermatology life quality index, being on systemic treatment and having a diagnosis of psoriatic arthritis is associated with increased costs in patients with plaque psoriasis.
    Ekelund M; Mallbris L; Qvitzau S; Stenberg B
    Acta Derm Venereol; 2013 Nov; 93(6):684-8. PubMed ID: 23603935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
    Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
    J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of Disease Activity and Quality of Life of Patients with Psoriasis after Narrow-band Ultraviolet B Therapy.
    Dourmishev LA; Lyubomirova K
    Folia Med (Plovdiv); 2020 Mar; 62(1):89-93. PubMed ID: 32337912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
    Strober BE; Sobell JM; Duffin KC; Bao Y; Guérin A; Yang H; Goldblum O; Okun MM; Mulani PM
    Br J Dermatol; 2012 Dec; 167(6):1374-81. PubMed ID: 22897348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis.
    Rencz F; Gulácsi L; Péntek M; Poór AK; Sárdy M; Holló P; Szegedi A; Remenyik É; Brodszky V
    Br J Dermatol; 2018 Nov; 179(5):1102-1108. PubMed ID: 29968311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry.
    Mease PJ; Blauvelt A; Sima AP; Beaty SW; Low R; Gomez B; Gurrola M; Lebwohl MG
    Dermatol Ther (Heidelb); 2024 Oct; 14(10):2805-2825. PubMed ID: 39283415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease Severity, Quality of Life, and Psychiatric Morbidity in Patients With Psoriasis With Reference to Sociodemographic, Lifestyle, and Clinical Variables: A Prospective, Cross-Sectional Study From Lahore, Pakistan.
    Khawaja AR; Bokhari SM; Tariq R; Atif S; Muhammad H; Faisal Q; Jafferany M
    Prim Care Companion CNS Disord; 2015; 17(3):. PubMed ID: 26644955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life.
    Gerdes S; Körber A; Biermann M; Karnthaler C; Reinhardt M
    J Dermatolog Treat; 2020 Aug; 31(5):470-475. PubMed ID: 32202943
    [No Abstract]   [Full Text] [Related]  

  • 40. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
    Zidane M; Dressler C; Gaskins M; Nast A
    JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.